Celon Pharma S.A. (WSE:CLN)

Celon Pharma Statistics

Total Valuation

Celon Pharma has a market cap or net worth of PLN 1.15 billion. The enterprise value is 1.14 billion.

Market Cap	1.15B
Enterprise Value	1.14B

Important Dates

The last earnings date was Wednesday, November 19, 2025.

Earnings Date	Nov 19, 2025
Ex-Dividend Date	n/a

Share Statistics

Celon Pharma has 53.86 million shares outstanding. The number of shares has decreased by -1.18% in one year.

Current Share Class	38.86M
Shares Outstanding	53.86M
Shares Change (YoY)	-1.18%
Shares Change (QoQ)	-2.57%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	12.39%
Float	23.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.10
PB Ratio	2.95
P/TBV Ratio	2.98
P/FCF Ratio	n/a
P/OCF Ratio	2,430.94
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-9.34
EV / Sales	5.07
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-27.72

Financial Position

The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.04.

Current Ratio	1.90
Quick Ratio	1.38
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	-0.34
Interest Coverage	-58.14

Financial Efficiency

Return on equity (ROE) is -27.03% and return on invested capital (ROIC) is -14.99%.

Return on Equity (ROE)	-27.03%
Return on Assets (ROA)	-12.84%
Return on Invested Capital (ROIC)	-14.99%
Return on Capital Employed (ROCE)	-26.86%
Revenue Per Employee	405,754
Profits Per Employee	-220,129
Employee Count	558
Asset Turnover	0.41
Inventory Turnover	2.82

Taxes

Income Tax	-4.05M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -18.98% in the last 52 weeks. The beta is 0.67, so Celon Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	-18.98%
50-Day Moving Average	21.76
200-Day Moving Average	23.23
Relative Strength Index (RSI)	49.41
Average Volume (20 Days)	13,030

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celon Pharma had revenue of PLN 225.60 million and -122.39 million in losses. Loss per share was -2.36.

Revenue	225.60M
Gross Profit	154.13M
Operating Income	-111.97M
Pretax Income	-126.45M
Net Income	-122.39M
EBITDA	-86.05M
EBIT	-111.97M
Loss Per Share	-2.36

Balance Sheet

The company has 21.03 million in cash and 14.19 million in debt, giving a net cash position of 6.84 million or 0.13 per share.

Cash & Cash Equivalents	21.03M
Total Debt	14.19M
Net Cash	6.84M
Net Cash Per Share	0.13
Equity (Book Value)	389.19M
Book Value Per Share	7.23
Working Capital	48.79M

Cash Flow

In the last 12 months, operating cash flow was 473,000 and capital expenditures -41.70 million, giving a free cash flow of -41.23 million.

Operating Cash Flow	473,000
Capital Expenditures	-41.70M
Free Cash Flow	-41.23M
FCF Per Share	-0.77

Margins

Gross margin is 68.32%, with operating and profit margins of -49.63% and -54.25%.

Gross Margin	68.32%
Operating Margin	-49.63%
Pretax Margin	-56.05%
Profit Margin	-54.25%
EBITDA Margin	-38.14%
EBIT Margin	-49.63%
FCF Margin	n/a

Dividends & Yields

Celon Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.18%
Shareholder Yield	1.18%
Earnings Yield	-10.64%
FCF Yield	-3.59%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Celon Pharma has an Altman Z-Score of 9.12 and a Piotroski F-Score of 3.

Altman Z-Score	9.12
Piotroski F-Score	3